Table 2.
Library | Compound | Previously Discovered | Mechanistic Class | Mechanistic Class Known to Reduce PNC |
---|---|---|---|---|
LOPAC | (S)-(+)-camptothecin | [10] | Topo I inhibitor | Yes |
7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine | No | Adenosine receptor antagonist | No | |
Diphenyleneiodonium chloride | No | Nitric oxide synthase inhibitor | No | |
Ellipticine | [10] | Intercalator | Yes | |
Etoposide | [10] | Topo II inhibitor | Yes | |
Genistein | Yes (our unpublished data) | Topo II inhibitor at high doses | Yes | |
Mitoxantrone | [10] | Intercalator | Yes | |
Methotrexate | [10] | Inhibits RNA synthesis | Yes | |
Quinacrine dihydrochloride | No | Intercalator | Yes | |
NCGC in house | Acriflavinium | Yes (our unpublished data) | Intercalator | Yes |
9-Aminoacridine | Yes (our unpublished data) | Intercalator | Yes | |
Daunorubicin | [10] | DNA intercalator and Topo II inhibitor | Yes | |
3,6-Diaminoacridine | Yes (our unpublished data) | Intercalator | Yes | |
Doxorubicin | [10] | DNA intercalator and Topo II inhibitor | Yes | |
Mofetil | No | Nucleoside analog | Yes | |
Topotecan | [10] | Topo I inhibitor | Yes | |
Zidovudine | No | Nucleoside analog | Yes | |
Tocris/Timtec | Actinomycin D | [10] | DNA intercalator and Topo II inhibitor | Yes |
Camptothecin | [10] | Topo I inhibitor | Yes | |
Chelidonine | No | Tubilin inhibitor | No | |
Prestwick | Camptothecin | [10] | Topo I inhibitor | Yes |
Daunorubicin | [10] | DNA intercalator and Topo II inhibitor | Yes | |
Doxorubicin | [10] | DNA intercalator and Topo II inhibitor | Yes | |
Biomol | Actinomycin D | [10] | DNA intercalator and Topo II inhibitor | Yes |
(S)-(+)-Camptothecin | [10] | Topo I inhibitor | Yes | |
Diphenyleneiodonium chloride | No | Nitric oxide synthase inhibitor | No | |
Hydroxy-camptothecin | No | Topo I inhibitor | Yes |
LOPAC, Library of Pharmacologically Active Compounds; NCGC, National Institutes of Health Chemical Genomics Center; PNC, perinucleolar compartment.